---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000005"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:16:43.726154+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025

## Summary
- Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.
- NX-5948 achieved 75.5% ORR in CLL patients; FDA Fast Track and EMA PRIME designations.
- Plans to initiate pivotal studies for NX-5948 in CLL in 2025; expand into WM and inflammatory indications.
- Gilead exercised option on IRAK4 degrader; Sanofi collaboration extended; STAT6 degrader candidate nomination expected H1 2025.
- Strengthened leadership: promoted Dr. O'Connor as CMO and Dr. Phiasivongsa as CTO; added Anil Kapur to board.

## SEC filing metadata
- accession: 0001549595-25-000005
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/0001549595-25-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000005/nrix-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000005
- JSON: https://secwatch.observer/filing/0001549595-25-000005.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.